Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ralph Palumbo

Pulmonary Disease Boca Raton, FL Medical Doctor

NPI 1295717718 CMS profile 103390

1601 Clint Moore Rd, 100, Boca Raton, FL 33487

Open in the dashboard

General payments

$6,168

205 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ralph Palumbo of Boca Raton, FL is reported in the CMS Open Payments database as having received $6,168 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,051 73
2024 General $714 26
2023 General $27 1
2022 General $15 1
2021 General $31 5
2020 General $366 16
2019 General $2,964 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ralph Palumbo
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ralph Palumbo were reported at $2,051. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ralph Palumbo Pulmonary Disease median Middle half National median
2019 $2,964 $377 $109–$1,340 $163
2020 $366 $230 $56–$907 $114
2021 $31 $269 $68–$1,072 $132
2022 $15 $390 $100–$1,457 $149
2023 $27 $419 $114–$1,659 $160
2024 $714 $476 $123–$1,818 $164
2025 $2,051 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,053 31 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $566 25 payments
  3. Actelion Pharmaceuticals US, Inc. $488 10 payments
  4. GlaxoSmithKline, LLC. $436 24 payments
  5. Mylan Specialty L.P. $367 16 payments
  6. Verona Pharma, Inc. $290 11 payments
  7. Insmed, Inc. $284 11 payments
  8. Harmony Biosciences LLC $193 4 payments
  9. Regeneron Healthcare Solutions, Inc. $138 6 payments
  10. Genzyme Corporation $127 6 payments
  11. Other $1,225 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,491 195 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,350 1 payment
  3. Education $327 9 payments
Products named General payments · program years 2019–2025
  1. BEVESPI AEROSPHERE $1,465 2 payments
  2. UPTRAVI $488 10 payments
  3. OPSUMIT $326 4 payments
  4. OFEV $310 12 payments
  5. Ohtuvayre $290 11 payments
  6. Arikayce $284 11 payments
  7. Yupelri Respiratory and Allergy $251 11 payments
  8. YUPELRI Anticholinergics, Inhaled $211 9 payments
  9. FASENRA $192 10 payments
  10. SYMBICORT $167 8 payments
  11. Other $3,001 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,432

Median for Pulmonary Disease: 936

Drug cost

$602,373

Median for Pulmonary Disease: $487,987

Branded share of claims

62.7%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 250 $218,975
Ofev Nintedanib Esylate Brand 13 $86,041
Breo Ellipta Fluticasone/Vilanterol Brand 155 $81,404
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 73 $49,171
Nucala Mepolizumab Brand 12 $44,266
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 28 $28,865
Spiriva Respimat Tiotropium Bromide Brand 28 $24,949
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 16 $14,105
Advair Diskus Fluticasone Propion/Salmeterol Brand 26 $12,692
Arnuity Ellipta Fluticasone Furoate Brand 15 $10,604

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$273,737

Medicare's payments for the services billed

Medicare patients

1,261

Average age 79

Services billed

3,377

712 women, 549 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Arthritis 62%
COPD 52%
Heart failure 42%
Atrial fibrillation 41%
Chronic kidney disease 41%
Diabetes 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YUPELRI
  • Mylan Specialty L.P. $105
$105 — —
DUPIXENT
  • GENZYME CORPORATION $50
  • Regeneron Healthcare Solutions, Inc. $40
$90 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $89
$89 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $61
$61 13 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record